KRMD KORU Medical Systems, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 704440 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY18.4%
TTM net income YoY77.8%
TTM EPS YoY92.9%
Revenue 3-yr CAGR17.3%
Net income 3-yr CAGR—
Margins
Gross margin63.6%
Operating margin-1.3%
Net margin-1.8%
FCF margin-0.8%
EBITDA margin0.4%
Returns
ROE-4.6%
ROA-2.9%
ROIC (approx.)-4.7%
Asset turnover1.66x
Leverage & solvency
Liabilities / assets32.6%
Debt / equity0.00x
Current ratio2.97x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.54x
Accruals ratio-4.5%
Payout ratio—
Capex / revenue1.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $11.57M | $12.05M | $11.76M | $10.90M | $10.40M | $10.19M | $9.64M | $8.84M |
| Cost of revenue | $4.02M | $4.20M | $4.53M | $4.08M | $4.14M | $3.72M | $3.59M | $3.28M |
| Gross profit | $7.55M | $7.85M | $7.23M | $6.82M | $6.26M | $6.48M | $6.05M | $5.56M |
| R&D expense | $1.28M | $1.07M | $1.32M | $1.14M | $933,107 | $1.19M | $1.11M | $1.11M |
| SG&A expense | $5.87M | $5.94M | $6.58M | $6.04M | $5.99M | $5.38M | $5.96M | $5.83M |
| Operating income | $187,118 | $626,991 | -$864,923 | -$547,104 | -$867,679 | -$312,655 | -$1.25M | -$1.59M |
| Pretax income | $236,103 | $258,249 | -$807,078 | -$482,172 | -$778,116 | -$189,511 | -$1.17M | -$1.56M |
| Income tax | $18,000 | $5,800 | — | $4,684 | -$150 | $17,356 | — | — |
| Net income | $218,103 | $252,449 | -$807,078 | -$486,856 | -$777,966 | -$206,867 | -$1.17M | -$1.56M |
| EBITDA | $397,141 | $837,022 | -$667,392 | -$367,930 | -$663,197 | -$103,168 | -$1.03M | -$1.38M |
| EPS (basic) | 0.00 | 0.01 | -0.02 | — | -0.02 | 0.00 | -0.03 | — |
| EPS (diluted) | 0.00 | 0.01 | -0.02 | — | -0.02 | 0.00 | -0.03 | — |
| Weighted avg. shares (diluted) | 46.73M | 49.51M | 46.36M | — | 46.24M | 46.19M | 45.98M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $7.36M | $8.29M | $8.77M | $8.87M | $8.46M | $8.05M | $8.74M | $9.58M |
| Receivables | $6.38M | $5.03M | $5.98M | $5.97M | $5.41M | $4.93M | $5.95M | $5.72M |
| Inventory | $4.69M | $4.51M | $4.48M | $3.68M | $4.41M | $3.95M | $3.28M | $2.80M |
| Current assets | $20.14M | $19.51M | $20.59M | $19.99M | $19.42M | $17.58M | $19.00M | $19.13M |
| PP&E, net | $4.00M | $3.93M | $4.34M | $4.47M | $4.24M | $4.37M | $4.53M | $4.29M |
| Intangibles | $1.68M | $1.66M | $711,211 | $684,841 | $681,621 | $698,974 | $716,326 | $730,279 |
| Total assets | $28.78M | $27.96M | $28.59M | $28.20M | $27.10M | $25.52M | $27.22M | $27.22M |
| Current liabilities | $6.79M | $7.18M | $8.85M | $8.19M | $7.83M | $6.05M | $7.80M | $7.20M |
| Total liabilities | $9.39M | $9.91M | $11.67M | $11.15M | $10.64M | $8.99M | $10.87M | $10.40M |
| Shareholders' equity | $19.40M | $18.05M | $16.92M | $17.05M | $16.46M | $16.53M | $16.35M | $16.81M |
| Shares outstanding | 46.38M | 46.15M | 46.13M | 46.37M | 46.29M | 46.23M | 46.14M | 45.96M |
| Cash flow statement | ||||||||
| Operating cash flow | -$882,830 | $216,113 | $14,663 | $1.09M | $65,456 | -$460,340 | -$237,467 | $939,615 |
| Capital expenditure | $268,219 | $107,907 | $46,163 | $407,782 | $52,483 | $28,814 | $443,438 | -$43,567 |
| Free cash flow | -$1.15M | $108,206 | -$31,500 | $686,974 | $12,973 | -$489,154 | -$680,905 | $983,182 |
| Investing cash flow | -$533,704 | -$577,367 | -$89,885 | -$421,655 | -$52,483 | -$28,814 | -$446,838 | $50,738 |
| Financing cash flow | $493,030 | -$118,816 | -$29,216 | -$264,908 | $396,330 | -$191,964 | -$160,808 | -$215,716 |
| Depreciation & amortization | $210,023 | $210,031 | $197,531 | $179,174 | $204,482 | $209,487 | $217,357 | $211,454 |
| Stock-based compensation | $927,868 | $457,774 | $681,510 | $972,812 | $627,393 | $415,744 | $697,590 | $699,789 |
Free plan shows the latest 8 periods; Pro shows all 67 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.